BNP Paribas Financial Markets Invests $416,000 in ZimVie Inc. (NASDAQ:ZIMV)

BNP Paribas Financial Markets bought a new stake in ZimVie Inc. (NASDAQ:ZIMV) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 29,824 shares of the company’s stock, valued at approximately $416,000. BNP Paribas Financial Markets owned about 0.11% of ZimVie as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Ancora Advisors LLC raised its position in ZimVie by 460.8% in the fourth quarter. Ancora Advisors LLC now owns 112,160 shares of the company’s stock valued at $1,565,000 after purchasing an additional 92,160 shares during the period. Northern Trust Corp raised its position in shares of ZimVie by 3.5% during the 4th quarter. Northern Trust Corp now owns 326,252 shares of the company’s stock worth $4,551,000 after acquiring an additional 10,988 shares in the last quarter. Mill Road Capital Management LLC acquired a new stake in ZimVie during the fourth quarter worth approximately $1,401,000. Price T Rowe Associates Inc. MD boosted its stake in ZimVie by 8.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 24,571 shares of the company’s stock valued at $343,000 after acquiring an additional 1,852 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in ZimVie by 9.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,244,938 shares of the company’s stock worth $17,367,000 after buying an additional 107,461 shares during the last quarter. 95.63% of the stock is currently owned by hedge funds and other institutional investors.

ZimVie Price Performance

ZimVie stock opened at $8.28 on Monday. The firm’s 50-day moving average is $9.58 and its two-hundred day moving average is $12.26. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.94 and a quick ratio of 1.38. The stock has a market capitalization of $230.57 million, a P/E ratio of -0.63 and a beta of 2.16. ZimVie Inc. has a 12-month low of $8.15 and a 12-month high of $22.40.

ZimVie (NASDAQ:ZIMV) last released its earnings results on Thursday, May 8th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.06. ZimVie had a negative net margin of 77.31% and a positive return on equity of 2.90%. The firm had revenue of $112.00 million during the quarter, compared to the consensus estimate of $113.10 million. Equities analysts predict that ZimVie Inc. will post 0.6 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ZIMV. B. Riley began coverage on shares of ZimVie in a report on Thursday, April 10th. They issued a “buy” rating and a $16.00 target price for the company. UBS Group lowered their target price on shares of ZimVie from $16.00 to $10.00 and set a “neutral” rating on the stock in a research report on Thursday, May 15th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of ZimVie in a research note on Wednesday, April 9th.

About ZimVie

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.